Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials

被引：0

作者：

Lebwohl, Mark ^{[1
]}

Warren, Richard B. ^{[2
]}

Kircik, Leon ^{[1
]}

Colston, Elizabeth ^{[3
]}

Hippeli, Lauren ^{[3
]}

Napoli, Andrew ^{[3
]}

Kisa, Renata M. ^{[3
]}

Banerjee, Subhashis ^{[3
]}

Menter, Alan ^{[4
]}

Thaci, Diamant ^{[5
]}

Blauvelt, Andrew ^{[6
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY USA

[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, NIHR Manchester Biomed Res Ctr, Manchester, England

[3] Bristol Myers Squibb, New York, NY USA

[4] Baylor Univ, Med Ctr, Waco, TX USA

[5] Univ Lubeck, Lubeck, Germany

[6] Oregon Med Res Ctr, Portland, OR USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

43851

引用

页码：AB35 / AB35

页数：1

共 50 条

[21] Deucravacitinib Improves Dermatology Life Quality Index (DLQI) in Patients with Moderate to Severe Psoriasis: Results fromthe Phase 3 POETYK PSO-1 and PSO-2 Trials
Augustin, Matthias
Strober, Bruce
Armstrong, April
Beaumont, Jennifer
Pham, Tan
Hudgens, Stacie
Zhuo, Joe
Becker, Brandon
Banerjee, Subhashis
Kisa, Renata
Papp, Kim
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 112 - 112
[22] Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast: Subset Analysis of Patients With Scalp Psoriasis in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
Thaci, Diamant
Rich, Phoebe
Sofen, Howard
Merola, Joseph
Strober, Bruce
Morita, Akimichi
Szepietowski, Jacek
Colston, Elizabeth
Throup, John
Wang, Tao
Banerjee, Subhashis
Blauvelt, Andrew
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 25 - 25
[23] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program
Warren, Richard B.
Armstrong, April W.
Imafuku, Shinichi
Paul, Carle
Kircik, Leon
Colston, Elizabeth
Scharnitz, Thomas
Wang, Tao
Banerjee, Subhashis
Strober, Bruce
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147
[24] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in psoriasis: efficacy analysis by prior treatment in the phase 3 POETYK PSO-1 and PSO-2 trials
Foley, Peter
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 65 - 65
[25] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials
Eisman, Samantha
Blauvelt, Andrew
Rich, Phoebe
Sofen, Howard
Lambert, Jo
Merola, Joseph
Lebwohl, Mark
Scharnitz, Thomas
Hoyt, Kim
Kisa, Renata M.
Banerjee, Subhashis
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 51 - 51
[26] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate/severe plaque psoriasis: onset of action in the phase 3 POETYK PSO-1 and PSO-2 trials
Foley, Peter
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 65 - 65
[27] Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials (vol 14, pg 2235, 2024)
Armstrong, April W.
Augustin, Matthias
Beaumont, Jennifer L.
Pham, Tan P.
Hudgens, Stacie
Gordon, Kenneth B.
Zhuo, Joe
Becker, Brandon
Zhong, Yichen
Kisa, Renata M.
Banerjee, Subhashis
Papp, Kim A.
DERMATOLOGY AND THERAPY, 2025, : 1037 - 1044
[28] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
Armstrong, A.
Gooderham, M.
Warren, R. B.
Papp, K.
Strober, B.
Thaci, D.
Colston, E.
Throup, J.
Kundu, S.
Banerjee, S.
Blauvelt, A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 795 - 796
[29] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast: subset analysis of patients with scalp psoriasis in the phase 3 POETYK PSO-1 and PSO-2 trials
Foley, Peter
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 66 - 66
[30] Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Achievement of Absolute PASI Thresholds in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Thaci, Diamant
Lebwohl, Mark
Gooderham, Melinda
Warren, Richard B.
Foley, Peter
Gottlieb, Alice B.
Banerjee, Subhashis
Hippeli, Lauren
Kisa, Renata
Griffiths, Christopher
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 119 - 120

← 1 2 3 4 5 →